RxDoctor Payments DataLook up a doctor →

Wendy Lee, MD

Rheumatology · Myrtle Beach, SCNPI 1154360675

Payments from drug & device makers

$23,674in general payments, 2019–2025

Across 1,148 payments — averaging $20.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$6K
  • AbbVie$4K
  • Amgen$2K
  • Novartis$2K
  • Johnson & Johnson$1K
  • UCB, Inc.$1K
  • plus $8K from 46 others

What the payments were for

  • Food & beverage$17,33199%
  • Education$2481%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,674 in reported general payments places this provider in the 70th percentile of 123 rheumatology providers in South Carolina.

See all rheumatology providers in South Carolina

Medicare billing

Part B allowed, 2024
$2,651,805
Medicare patients
677
Services billed
179,883

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab126$1,035,166
RinvoqUpadacitinib65$545,401
Enbrel SureclickEtanercept39$331,648
Xeljanz XrTofacitinib Citrate15$97,571
OlumiantBaricitinib17$87,716
OtezlaApremilast13$82,209
Humira PenAdalimumab11$72,135
KevzaraSarilumab11$46,853
Leflunomide534$30,091
MethotrexateMethotrexate Sodium952$24,727
Hydroxychloroquine Sulfate638$22,087
SavellaMilnacipran Hcl27$19,351
Gabapentin921$18,573
HorizantGabapentin Enacarbil13$13,646
Duloxetine Hcl473$13,342

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Savella$3,670$564,75292 claims
Lilly USA, LLCOlumiant$703$87,71617 claims
AmgenOtezla$2,102$82,20913 claims
SanofiKevzara$69$46,85311 claims
Arbor Pharmaceuticals, Inc.Horizant$14$13,64613 claims
Scilex Pharmaceuticals Inc.Colchicine$24$2,31231 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil$89$1,07815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 123 rheumatology providers in South Carolina.

Other rheumatology in Myrtle Beach

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →